<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93994">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785355</url>
  </required_header>
  <id_info>
    <org_study_id>005</org_study_id>
    <secondary_id>00022</secondary_id>
    <nct_id>NCT01785355</nct_id>
  </id_info>
  <brief_title>The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients</brief_title>
  <acronym>PAROHEM</acronym>
  <official_title>Periodontal Disease, Inflammation, Nutritional Status And Anaemia Response To Erythropoietin In Chronic Haemodialyzed Patients - The Impact Of Treatment For Periodontal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anemia Working Group Romania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anemia Working Group Romania</source>
  <oversight_info>
    <authority>Romania: Ministry of Public Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies revealed a direct relationship between the severity of periodontal
      inflammation and CRP (NHANES III, Dumitriu HT et al, 1998). In patients without any other
      source of inflammation but PDD, proper dental treatment of the disease decreased CRP to
      normal levels (Dumitriu H.T. et al., 1998; D'Aiuto F. et al, 2004; Borawski J. et al., 2007)
      Moreover, a direct link between high levels of CRP and atherosclerotic complications has
      been found in studies conducted both in general population (Ridker PM, et al., 1998; Koenig
      W, et al., 1999) and in HD subjects (Westhuyzen J, et al., 2000; Iseki K., et al., 1999;
      Zimmermann J, et al. 1998).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Modification of nutritional status</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>SGA, whole body bioimpedance, biochemical parameters (serum albumin, predialysis serum urea, serum creatinine, serum phosphates)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification of inflammatory status</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>C Reactive Protein</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Modification of periodontal disease index</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modification of periodontal disease index assessed by the CAL, PPD, bleeding index</description>
  </other_outcome>
  <other_outcome>
    <measure>Modification of the quality of life, as assessed by SF-36 and OHIP-14</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modification of the quality of life, as assessed by SF-36 and OHIP-14</description>
  </other_outcome>
  <other_outcome>
    <measure>Modification of anaemia response to epoetin</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modification of anaemia response to epoetin, as assessed by the ERI and by the cumulative ESAs dose</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Periodontal Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Dental treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dental treatment</intervention_name>
    <description>The preliminary stage deals with:
assessment of the clinical state of the patient by completing a detailed dental and periodontal chart
education of the patient regarding correct oral hygiene habits;
Phase I Therapy:
plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)
evaluation of response to the treatment
Phase II Therapy - surgical phase:
extraction of hopeless teeth
evaluation of the surgical results.
Maintenance phase:
periodic reevaluation of plaque and calculus and of periodontal conditions.</description>
    <arm_group_label>Dental treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialyzed patients with periodontal disease

        Exclusion Criteria:

          -  Malignancies, Diabetes

          -  Patient refusal to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oana Slusanschi, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy Bucharest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMI &quot;Dr Slusanschi Oana&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Anemia Working Group Romania</investigator_affiliation>
    <investigator_full_name>Oana Slusanschi</investigator_full_name>
    <investigator_title>DMD</investigator_title>
  </responsible_party>
  <keyword>periodontal disease</keyword>
  <keyword>CKD</keyword>
  <keyword>nutrition</keyword>
  <keyword>inflammation</keyword>
  <keyword>anemia response to ESA</keyword>
  <keyword>quality of life</keyword>
  <keyword>hemodialysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
